Advertisement
Advertisement
U.S. markets open in 8 hours 23 minutes
Advertisement
Advertisement
Advertisement
Advertisement

United Therapeutics Corporation (UTHR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
218.73-2.92 (-1.32%)
At close: 04:00PM EDT
213.00 -5.73 (-2.62%)
After hours: 07:58PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close221.65
Open220.44
Bid0.00 x 800
Ask0.00 x 3000
Day's Range212.02 - 222.95
52 Week Range158.38 - 245.48
Volume574,681
Avg. Volume501,961
Market Cap9.956B
Beta (5Y Monthly)0.53
PE Ratio (TTM)16.53
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
15% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for UTHR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • United Therapeutics Corporation
    Analyst Report: United Therapeutics CorporationUnited Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
    Rating
    Fair Value
    Economic Moat
    22 days agoMorningstar
View more
  • Business Wire

    United Therapeutics Corporation Reports Second Quarter 2022 Financial Results

    SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., August 03, 2022--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2022. Total revenues in the second quarter of 2022 grew 5% year-over-year to $466.9 million, compared to $446.5 million in the second quarter of 2021.

  • Business Wire

    United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022

    SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., July 27, 2022--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2022 financial results before the market opens on Wednesday, August 3, 2022.

  • Business Wire

    United Therapeutics Provides an Update on Its Organ Printing Programs

    SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & ROCK HILL, S.C., June 06, 2022--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that in partnership with 3D Systems Corporation (NYSE: DDD) it has produced the world’s most complex 3D-printed object – a human lung scaffold – and demonstrated it at the LIFE ITSELF Conference that occurred May 31 to June 3, 2022 in San Diego. The event was organized and hosted by Dr. Sanjay Gupta and Marc Hodosh and w

Advertisement
Advertisement